# US 2019/0314465 A1 · Method for promoting insulin secretion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314465 A1
- Document ID: US20190314465A1
- Status: Published application
- Kind: A1
- Application number: 16/470,120
- Filed: 2017-06-19
- Published: 2019-10-17
- Earliest claimed: 2016-12-15
- Assignees: Talengen International Limited
- Applicants: Talengen International Limited
- Inventors: Jinan LI
- Web page: https://patentgrep.com/patent/US20190314465A1

## CPC

- A61K 38/484: {Plasmin (3.4.21.7)}
- A61K 38/43: Enzymes; Proenzymes; Derivatives thereof
- A61K 38/48: acting on peptide bonds (3.4)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- C12Y 304/21007: Plasmin (3.4.21.7), i.e. fibrinolysin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present invention relates to a method for promoting insulin secretion comprising administering an effective amount of plasminogen to a subject; furthermore, the present invention relates to a medicament for promoting insulin secretion.

## Claims

### Claim at position 1

1-56. (canceled)

### Claim 57

A method for treating diabetes mellitus, comprising administering an effective amount of plasminogen to a diabetic subject to promote secretion of insulin in the diabetic subject.

### Claim 58 (depends on 57)

The method of claim 57, wherein the diabetes mellitus is T1DM or T2DM.

### Claim 59 (depends on 57)

The method of claim 57, wherein the plasminogen promotes secretion of insulin in the diabetic subject after eating.

### Claim 60 (depends on 57)

The method of claim 57, wherein the plasminogen promotes secretion of insulin in the diabetic subject in a fasted state.

### Claim 61 (depends on 57)

The method of claim 57, wherein the plasminogen returns blood glucose to a normal or nearly normal level by promoting secretion of insulin in response to a stimulation of elevated blood glucose in the diabetic subject.

### Claim 62 (depends on 57)

The method of claim 57, wherein the plasminogen reduces expression and/or secretion of glucagon in the subject while promoting the expression and/or secretion of insulin.

### Claim 63 (depends on 62)

The method of claim 62, wherein the plasminogen achieves a return to a normal or nearly normal level of blood glucose in the subject by reducing expression and/or secretion of glucagon in the subject while promoting the expression and/or secretion of insulin.

### Claim 64 (depends on 57)

The method of claim 57, wherein the plasminogen promotes expression of insulin receptor substrate 2 (IRS-2).

### Claim 65

A method for promoting repair of an inflammation in the pancreatic islet, comprising administering an effective amount of plasminogen to the subject.

### Claim 66 (depends on 65)

The method of claim 65, wherein the plasminogen promotes expression of cytokine TNF-α.

### Claim 67 (depends on 65)

The method of claim 65, wherein the plasminogen promotes expression of multi-directional nuclear transcription factor NF-κB in the subject.

### Claim 68 (depends on 65)

The method of claim 65, wherein the plasminogen reduces collagen deposition in the pancreatic islet.

### Claim 69 (depends on 65)

The method of claim 65, wherein the plasminogen reduces pancreatic islet fibrosis.

### Claim 70 (depends on 65)

The method of claim 65, wherein the plasminogen inhibits pancreatic islet cell apoptosis.

### Claim 71 (depends on 57)

The method of claim 57, wherein the plasminogen is administered in combination with one or more other drugs or therapies.

### Claim 72 (depends on 71)

The method of claim 71, wherein the plasminogen is administered in combination with one or more drugs selected from anti-diabetic drugs, drugs against cardiovascular and cerebrovascular diseases, anti-thrombotic drugs, anti-hypertensive drugs, antilipemic drugs, anticoagulant drugs, and anti-infective drugs.

### Claim 73 (depends on 57)

The method of claim 57, wherein the plasminogen has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID No. 2, and still has the plasminogen activity.

### Claim 74 (depends on 57)

The method of claim 57, wherein the plasminogen is a protein that comprises a plasminogen active fragment and still has the plasminogen activity.

### Claim 75 (depends on 57)

The method of claim 57, wherein the plasminogen is selected from Glu-plasminogen, Lys-plasminogen, mini-plasminogen, micro-plasminogen, delta-plasminogen or their variants that retain the plasminogen activity.

### Claim 76 (depends on 57)

The method of claim 57, wherein the plasminogen is a natural or synthetic human plasminogen, or a variant or fragment thereof that still retains the plasminogen activity.

### Claim 77 (depends on 57)

The method of claim 57, wherein the plasminogen is administered to the subject at a dosage of 1-100 mg/kg, 1-50 mg/kg, or 1-10 mg/kg, daily, every other day, or weekly.

### Claim 78 (depends on 77)

The method of claim 77, wherein the dosage of the plasminogen is preferably repeated at least once.

### Claim 79 (depends on 77)

The method of claim 77, wherein the plasminogen is preferably administered at least daily.
